Literature DB >> 7018874

Prostacyclin and blood coagulation.

S Moncada, J R Vane.   

Abstract

Prostacyclin is a potent but unstable vasodilator, and inhibitor of platelet aggregation, which is produced by blood vessel walls. Platelet aggregability may be constantly conditioned in vivo by local or circulating prostacyclin. Prostacyclin is important in the maintenance of vascular homeostasis and may be implicated in certain disease states. The use of prostacyclin in antithrombotic therapy appears logical, considering its action in increasing platelet cyclic AMP and reducing aggregation; its potential in antithrombotic therapy is presently being explored.

Entities:  

Mesh:

Substances:

Year:  1981        PMID: 7018874     DOI: 10.2165/00003495-198121060-00002

Source DB:  PubMed          Journal:  Drugs        ISSN: 0012-6667            Impact factor:   9.546


  24 in total

Review 1.  Pharmacology and endogenous roles of prostaglandin endoperoxides, thromboxane A2, and prostacyclin.

Authors:  S Moncada; J R Vane
Journal:  Pharmacol Rev       Date:  1978-09       Impact factor: 25.468

2.  Arachidonic acid metabolites and the interactions between platelets and blood-vessel walls.

Authors:  S Moncada; J R Vane
Journal:  N Engl J Med       Date:  1979-05-17       Impact factor: 91.245

3.  Studies on the role of lipoperoxides in human pathology. II. The presence of peroxidized lipids in the atherosclerotic aorta.

Authors:  J GLAVIND; S HARTMANN; J CLEMMESEN; K E JESSEN; H DAM
Journal:  Acta Pathol Microbiol Scand       Date:  1952

4.  A double blind placebo controlled crossover study of prostacyclin in man.

Authors:  G A FitzGerald; L A Friedman; I Miyamori; J O'Grady; P J Lewis
Journal:  Life Sci       Date:  1979-08-20       Impact factor: 5.037

5.  Circulatory and anti-platelet effects of intravenous prostacyclin in healthy men.

Authors:  A Szczeklik; R J Gryglewski; R Nizankowski; J Musiał; R Pietoń; J Mruk
Journal:  Pharmacol Res Commun       Date:  1978-06

6.  Prostacyclin is a circulating hormone.

Authors:  S Moncada; R Korbut; S Bunting; J R Vane
Journal:  Nature       Date:  1978-06-29       Impact factor: 49.962

7.  Stimulation of prostacyclin release from vessel wall by Bay g 6575, an antithrombotic compound.

Authors:  J Vermylen; D A Chamone; M Verstraete
Journal:  Lancet       Date:  1979-03-10       Impact factor: 79.321

8.  Production of 6-oxo-PGF1 alpha by human lung in vivo.

Authors:  C N Hensby; P J Barnes; C T Dollery; H Dargie
Journal:  Lancet       Date:  1979-12-01       Impact factor: 79.321

9.  Thromboxane generation and platelet aggregation in survivals of myocardial infarction.

Authors:  A Szczeklik; R J Gryglewski; J Musiał; L Grodzińska; M Serwońska; E Marcinkiewicz
Journal:  Thromb Haemost       Date:  1978-08-31       Impact factor: 5.249

10.  Effects of intravenous infusion of prostacyclin (PGI2) in man.

Authors:  J O'Grady; S Warrington; M J Moti; S Bunting; R Flower; A S Fowle; E A Higgs; S Moncada
Journal:  Prostaglandins       Date:  1980-02
View more
  3 in total

1.  Iloprost for prevention of contrast-mediated nephropathy in high-risk patients undergoing a coronary procedure. Results of a randomized pilot study.

Authors:  K Spargias; E Adreanides; G Giamouzis; S Karagiannis; A Gouziouta; A Manginas; V Voudris; G Pavlides; D V Cokkinos
Journal:  Eur J Clin Pharmacol       Date:  2006-07-11       Impact factor: 2.953

Review 2.  Pharmacologic treatments for pulmonary hypertension: exploring pharmacogenomics.

Authors:  Julio D Duarte; Rebekah L Hanson; Roberto F Machado
Journal:  Future Cardiol       Date:  2013-05

Review 3.  The role of renin-angiotensin system activated phagocytes in the SARS-CoV-2 coronavirus infection.

Authors:  Laszlo Göbölös; István Rácz; Maurice Hogan; Ernő Remsey-Semmelweis; Bassam Atallah; Wael AlMahmeed; Fahad AlSindi; Rakesh M Suri; Gopal Bhatnagar; Emin Murat Tuzcu
Journal:  J Vasc Surg       Date:  2020-12-18       Impact factor: 4.268

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.